SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending due to a contentious short report from Muddy Waters, which has triggered heavy selling volume and intense debate among retail investors. The community remains deeply divided, with many traders dismissing the report as a coordinated "short and distort" tactic to facilitate short covering, while others express growing concern over the potential impact of the allegations on management's credibility.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is currently under intense scrutiny following reports that an audit prompted a major advertising holding company to advise clients against using the platform, sparking volatility and fueling concerns about the firm's transparency and future growth. Investors remain deeply divided, with some pointing to significant insider buying as a sign of value while others focus on negative sentiment, persistent short-selling pressure, and the search for a new CFO as reasons to stay cautious.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus fueled by a flurry of strategic acquisitions and a high-profile partnership with Palantir that has bolstered its status as an emerging defense prime. While the stock experiences significant intraday volatility and selling pressure, the community remains heavily bullish, fixated on the upcoming earnings report and the company's potential to secure major government defense contracts in an increasingly drone-centric global threat landscape.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending following a massive $27 billion AI infrastructure deal with Meta, which effectively cements its status as a leading hyperscaler. While the stock initially surged, it faced downward pressure due to the announcement of a $3.75 billion convertible senior notes offering, sparking intense debate among investors over whether the move represents necessary capital-intensive growth or dilutive overreach.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing increased investor activity as the market prepares for quarterly earnings, with the community actively speculating on potential buyout rumors and monitoring the ramp-up of BRIUMVI sales. Investors are particularly focused on company revenue guidance and the progress of the subcutaneous pipeline as catalysts that could influence the stock's current trading range.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is trending as traders speculate on the aggressive price action following its public debut, with the community actively debating its potential as a low-float play within the drone and defense technology sector. While some are focused on the volatility and IPO-driven momentum, others are highlighting the stock's exposure to AI-driven autonomous systems and battlefield-tested software.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is experiencing heightened volatility and intense trader interest as the market weighs strong revenue growth and new AI-focused product milestones against broader concerns about copper-versus-optic connectivity trends. The community is actively debating the stock's long-term valuation and potential for institutional accumulation, with many traders closely watching price levels following significant intraday swings.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as investors weigh conflicting forces of milestone euphoria, following a NRC license win for its subsidiary, against pre-earnings anxiety. While the community is actively debating the company's valuation, insider activity, and the viability of its long-term nuclear power narrative for AI, options volume remains high with market participants bracing for significant post-earnings volatility.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon shares are facing intense volatility and downward pressure as investors react to a lack of leadership clarity, a brewing proxy fight with founder Chip Wilson, and broader concerns regarding consumer discretionary spending. While some traders are betting on a potential value recovery or activist-driven turnaround, the community remains divided between those viewing current levels as a generational buying opportunity and others concerned about deteriorating brand momentum and competitive headwinds.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as a major beneficiary of the AI infrastructure boom, with investors closely watching for a breakout ahead of its upcoming earnings report. The stock is seeing significant institutional interest and price target upgrades driven by supply shortages and strong demand for high-bandwidth memory (HBM) used in advanced AI systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ardelyx Touts IBSRELA's 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan

Ardelyx (NASDAQ:ARDX) executives outlined commercial momentum for IBSRELA and XPHOZAH, key investment priorities for 2026, and development plans for a chronic idiopathic constipation (CIC) expansion...

Vanguard Group Inc. Boosts Holdings in Ardelyx, Inc. $ARDX

Vanguard Group Inc. grew its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 14.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Ardelyx (NASDAQ:ARDX) Stock Passes Below 200-Day Moving Average - What's Next?

Ardelyx (NASDAQ:ARDX) Stock Price Crosses Below Two Hundred Day Moving Average - Here's What Happened...

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

Key PointsMichael Raab sold 41,666 shares directly on Feb. 24, 2026, for approximately $261,000 at a weighted-average price of $6.25 per share...

Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity

Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity...

<ul class="summary-bullets"><li>Director David Mott bought 333,333 shares at a weighted average price of $5.84, lifting his stake to more than 3.3 million shares.</li><li>The insider buy followed a mixed Q4 earnings report in which revenue rose to $125.2 million, beating expectations, while earnings remained flat.</li><li>Ibsrela drove the revenue beat, offsetting softer Xphozah sales, and the company guided for Ibsrela revenue of $410 million to $430 million in 2026.</li></ul>Ardelyx shares jumped more than 5% overnight after a board director made a sizable open-market purchase, adding fuel to growing investor confidence in Ibsrela, the company’s flagship constipation drug.<a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> rose 0.4% on Monday after tumbling 15% on Friday, when the company reported no earnings for the fourth quarter (Q4).<h2 class="st-heading-2">Ardelyx Director Buys 333K Shares In Open Market</h2>According to a new regulatory filing, David Mott, a director at Ardelyx, purchased 333,333 shares of the company’s stock on Friday at a weighted average price of $5.84 per share.The filing shows the purchase was made in multiple open-market transactions, with prices ranging from $5.67 to $6.00. Following the buy, Mott holds over 3.3 million Ardelyx shares.&nbsp;<h2 class="st-heading-2">Ibsrela Drives Q4 Revenue Beat</h2>The insider buy followed Ardelyx’s Q4 earnings report, where revenue rose to $125.2 million, up from $116.1 million a year earlier. The result topped Wall Street expectations of about $119.4 million.The company said the increase was driven largely by higher adoption of Ibsrela, which is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Growth in Ibsrela helped offset softer sales from Xphozah, Ardelyx’s drug for lowering phosphate levels in patients with chronic kidney disease on dialysis.Earnings per share came in at $0.0, compared with $0.02 in the year-ago quarter and slightly below expectations of $0.01.<h2 class="st-heading-2">Strong 2026 Outlook Anchored By Ibsrela</h2>Alongside the results, Ardelyx expects Ibsrela revenue of $410 million to $430 million in 2026, representing growth of at least 50% from 2025 levels. The company cited improvements in prescribing across target healthcare providers, higher patient engagement, and stronger prescription pull-through. For Xphozah, the company forecast 2026 revenue of $110 million to $120 million, up from $103.6 million in 2025.Ardelyx also said it is running additional programs to evaluate Ibsrela in chronic idiopathic constipation and continues to advance its experimental asset RDX10531 across multiple potential indications.<h2 class="st-heading-2">Analysts Reaffirm Bullish Views</h2>On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels. Meanwhile, H.C. Wainwright raised its target by 80% to $18 from $10 on Friday, while reiterating a ‘Buy’ rating.H.C. Wainwright said it was encouraged by Ardelyx securing a new U.S. patent extending to November 2042, covering oral formulations of Tenapor, including Ibsrela and Xphozah. Ardelyx has since confirmed that both drugs are now listed in the FDA’s Orange Book, marking a step that strengthens intellectual property protection.CEO Mike Raab previously said the listing was “an important step in extending protections for our portfolio of first-in-class medicines.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for ARDX was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/rdx_ss_png_9ca239304b.webp" alt="rdx ss.png" width="968" height="140"><figcaption>ARDX sentiment and message volume as of February 24 | Source: Stocktwits</figcaption></figure>One user said, “Maybe retailers will realize now’s the time to buy. Nice buy by mott ”<stembedurl>https://stocktwits.com/mktfixer/message/645684167</stembedurl>Another user said, “Always nice seeing Mr.Mott’s investing in the company. Clearly, he’s in it to win it. He knows what he owns and how the current strategy will be a success. So swell! “<stembedurl>https://stocktwits.com/imlivinit/message/645684336</stembedurl>ARDX stock has declined 1.4% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug

On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.

Equity

Insider Selling: Ardelyx (NASDAQ:ARDX) Insider Sells $47,829.60 in Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Laura Williams sold 8,176 shares of Ardelyx stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85...

Ardelyx (NASDAQ:ARDX) Insider Sells 10,439 Shares

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Eric Duane Foster sold 10,439 shares of the firm's stock in a transaction on Friday, February 20th. The stock was sold at an average price of...

Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 45,982 Shares of Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 45,982 shares of the company's stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85...

Ardelyx (NASDAQ:ARDX) Director Purchases $1,946,664.72 in Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) Director David Mott purchased 333,333 shares of the business's stock in a transaction dated Friday, February 20th. The shares were purchased at an...

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

ARDX
Ardelyx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARDX News

ARDXArdelyx Inc